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Background: Active surveillance is considered a mainstream strategy in the management of patients with low-risk
prostate cancer. A mission-critical step in implementing a robust active surveillance program and plan its resource
and service requirements, is to gauge its current practice across the United Kingdom. Furthermore it is imperative
to determine the existing practices in the context of the recommendations suggested by the recent National
Institute for Health and Clinical Excellence guidance on active surveillance of prostate cancer.
Methods: An internet questionnaire was circulated to urologists, clinical oncologists and urology nurse specialists
across three geographically distinct cancer networks. Twenty five questions across four domains were assessed.
(i) hospital resources (staff and clinical areas) utilised for active surveillance (ii) enrolment criteria (iii) follow up (iv)
criteria that trigger conversion to active treatment.
Results: We received 35 responses, 20 of which were from urologists. The survey data suggests that there is
marked heterogeneity in enrolment criteria with patients having features of intermediate-risk prostate cancer often
recruited into Active Surveillance programs. Only 60 % of our respondents use multiparametric MRI routinely to
assess patient suitability for active surveillance. In addition, marked variation exists in how patients are followed
up with regard to PSA testing intervals and timing of repeat biopsies. Only 40 % undertake a repeat biopsy at
12 months. Tumour upgrading on repeat biopsy, an increase in tumour volume or percentage of core biopsies
involved would prompt a recommendation for treatment amongst most survey respondents. In addition allocation
of resources and services for active surveillance is poor. Currently there are no dedicated active surveillance clinics,
which are well-structured, -resourced and -supported for regular patient counselling and follow up.
Conclusion: This variability in enrolment criteria and follow up is also demonstrated in international and national
series of active surveillance. Resources are not currently in place across the UK to support an active surveillance
program and a national discussion and debate to plan resources is much required so that it can become a
mainstream therapeutic strategy.
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Table 1 Protocol for Active Surveillance as outlined by NICE:
prostate cancer: diagnosis and treatment (CG175)
Timing Tests
At enrolment in active
surveillance
Multiparametric MRI if not previously
performed
Year 1 of active surveillance Every 3–4 months: measure PSA
Throughout active surveillance:
monitor PSA kinetics
Every 6–12 months: DRE
At 12 months prostate rebiopsy
Years 2–4 of active surveillance Every 3–6 months: measure PSA
Throughout active surveillance:
monitor PSA kinetics
Every 6–12 months: DRE
Year 5 and every year thereafter
until active surveillance ends
Every 6 months: measure PSA
Throughout active surveillance:
monitor PSA kinetics
Every 12 months: DRE
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There is a clear trend, both in the UK and worldwide, to-
wards managing patients diagnosed as having low-risk
prostate cancer (LRPC) with active surveillance (AS) [1, 2].
The recent publication of the Prostate Cancer Intervention
Versus Observation Trial (PIVOT) has further added to
the growing evidence which supports that LRPC can be
safely managed by AS and without the treatment-related
side effects [3]. There are however major caveats in consid-
ering widespread adoption of AS for LRPC in the UK and
indeed in other health-care systems. Firstly, there is an
increasing concern that the current diagnostic method of
an elevated prostate specific antigen (PSA), digital rectal
examination (DRE) and a single 10–12 core trans-rectal bi-
opsy, carries a significant potential of missing higher risk
disease. Secondly there remain no universally accepted in-
clusion criteria for AS and there is a lack of consensus on
what an AS regime should consist of. Whereas there are
national and international guidelines on standards of sur-
gery and radiotherapy for prostate cancer these are lacking
for AS [4]. Thirdly, the timing of PSA checks, repeat
examination, place and role of imaging, repeat biopsies
and triggers for intervention vary considerably from
centre to centre and even from clinician to clinician. Fi-
nally, AS requires structured, well-resourced and sup-
ported clinics for regular patient reviews, and these will be
needed for many years. It is therefore clear that an expan-
sion of AS will be a significant resource implication for
any health service let alone an already overstretched Na-
tional Health Service (NHS).
A move to a wider implementation of AS will require
in addition to a uniform protocol, a national consensus
on the resource and service requirements in setting this
up and on the likely cost-implications of a long-term AS
programme. As an initial step in this process the recent
publication of the updated National Institute for Health
and Clinical Excellence (NICE) guidance (CG175) has
proposed a guideline for how men on AS may be managed
(Table 1) [5]. A mission-critical step however in any at-
tempt to adopt this guideline, is to gauge how AS is cur-
rently practiced in the UK.
Methods
We conducted an online survey of urologists, clinical
oncologists (these were both medical and radiation on-
cologists with a special interest in uro-oncology) and ur-
ology nurse specialists with regard to the practice of AS
within the East of England (EoE) cancer network. Data
was collected during the year 2012–2013. The EoE can-
cer network delivers cancer care to 2.63 million people
and is comprised mainly of two university hospitals and
six district general hospitals. It employs approximately
50 consultant urologists. An internet questionnaire was
circulated by email to urological departments of theeight hospitals within the network. The email address of
each urological department within each hospital was
available on the hospital website. After receiving the
email secretarial staff within each hospital were able to
forward the questionnaire to all urological consultants,
oncologists and urology nurse specialists working within
each hospital. A further email was sent 1 month after in
order to remind non-responders to complete the ques-
tionnaire. We also distributed the survey to two other
cancer networks in geographically distinct areas of the
UK. These were the North of England Cancer network
and the Avon Somerset and Wiltshire cancer network.
The reason behind the inclusion of a further two geo-
graphically distinct cancer networks was that we felt that
this would allow us to form a more comprehensive opin-
ion on the practice of AS across the UK and also allow
comparison of our practice with other networks. Twenty
five questions across four domains were assessed with
associated multiple-choice answers (Additional file 1).
Where more than one answer was possible respondents
were able to select more options. The four domains
were: (i) what hospital resources are currently utilised
(staff and clinical areas) to counsel and follow up patients
on AS (ii) enrolment criteria for AS (iii) how patients on
AS are followed up (iv) respondents opinions on criteria
that would trigger conversion to active treatment. Results
were collated and rounded up to the closest percentage
and represent the frequency of the answer selected for a
particular question against the number of respondents an-
swering the question.
Ethics approval
The above study is registered as an audit at Adden-
brooke’s hospital NHS trust. Ref: 3631.
Table 2 Distribution of responses according to specialty
Specialty Response percent (%) Response count
Urology 57 20
Medical oncology 0 0
Clinical oncology 20 7
Urology specialist nurse 20 7
Oncology specialist nurse 3 1
Total 35
Skipped question 0
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Completed questionnaires were received from 15 urolo-
gists, six clinical oncologists and four specialist nurses
within our cancer network with all invited trusts taking
part. We received a further 10 responses from the other
two cancer networks we surveyed (Table 2). From the 35
respondents, 31 were directly involved in managing pa-
tients on AS with most centres reported managing more
than 30 men a year by AS.Current setting of AS
Resources allocated to AS counselling were first assessed
(Fig. 1). Dedicated urology prostate cancer clinics were
used in 74 % of cases but counselling and reviews also
occurred in general urology clinics, oncology clinics,
joint oncology and urology clinics as well as nurse ledFig. 1 Responses on the resources currently utilised to counsel men on AS
particular question against the number of respondents answering the quesclinics. AS counselling was primarily done by urologists
in 75 % of cases. However oncologists and nurse special-
ists were also actively involved in this process. Respon-
dents were then asked about the existence of an AS policy
used in their unit. Of all respondents 68 % reported the
use of a policy to guide selection of men suitable for AS.
The rest however stated of not being aware of any agreed
policy. These results suggest that currently there is little
evidence of a dedicated service for men managed by AS
within current NHS resource provisions.Enrolment criteria for AS
Respondents were then asked about different enrolment
criteria used in enlisting patients to their AS programme
(Fig. 2a). With regards to age, there was a strong agree-
ment that AS would not be considered in men of 55 years
or younger. A sizeable proportion (46 %) would not con-
sider it in men over 75 years either with the preference
here being for watchful waiting. There was a strong agree-
ment also that a classical definition of low risk (Gleason
score of 6, a PSA level of ≤10 ng/ml and a TNM stage of ≤
T2) were necessary for enrolment into an AS programme.
Some would also consider a PSA level between 10 and
20 ng/ml as long as other characteristics such as Gleason
score and TNM stage were favourable. 64.5 % and 29 % of
respondents would consider patients for AS if the TNM
stage was T2b or T2c respectively. A significant majority
considered the number of cores involved as well as the. The percentage represents the frequency of the answer selected for a
tion
Fig. 2 a Opinions on enrolment criteria for AS. b Opinions on enrolment criteria for AS
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cision making for AS enrolment. Specifically, 17 % would
not be deterred from AS if more than 50 % of total number
of cores biopsied were involved as long as the Gleason
score is 6. We also observed that patients were being en-
rolled in programs with characteristics of intermediate risk
prostate cancer (Fig. 2b). Interestingly, nearly 70 % wouldconsider AS in patients with a Gleason score of 7 if
other tumour characteristics such as TNM stage, age,
PSA level and information on biopsy core involvement
were favourable. 58.3 % routinely use multiparametric
MRI (mp MRI) and 29.2 % perform an early repeat bi-
opsy (TRUS or template) within 3 months to aid in the
selection of patients suitable for AS. These findings
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standardisation in the inclusion criteria for men on AS
across hospitals even within a single network.
Follow up of patients on AS
Respondents were asked about how they followed up
patients on AS (Fig. 3a). The majority of respondents
(62 %) indicated that they followed patients up with 3Fig. 3 a Responses on how men on AS are currently followed up. b Respomonthly PSA at least in the first 2 years on AS and nearly
40 % would carry out the first repeat biopsy within
12 months. A significant minority however would only re-
biopsy if there was evidence of change in the serum PSA
or other clinical changes. Most respondents (60 %) used
DRE as an integral part of AS monitoring. The vast major-
ity did not use MRI as a tool to monitor men on AS. Fol-
low up was undertaken in a multidisciplinary setting withnses on resources currently utilised to follow up men on AS
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specialists involved in patient care (Fig. 3b). This however
did not often occur in dedicated AS prostate cancer clinics
but mainly in clinician led general urology clinics. There
was also a mixture of follow up methods including PSA
chart books and telephone checks. A majority of respon-
dents also stated that they felt it was important to give
patients on AS certain life-style and dietary advice either
verbally or in the form of a patient information leaflet.
Finally, we asked what would trigger a recommendation
for active treatment. Here there was broad agreement that
tumour upgrading on repeat biopsy or an increase in
tumour volume or percentage of core biopsies involved
would prompt a recommendation for treatment. Half of
our respondents however would recommend active treat-
ment based on evidence of a rising PSA alone or an in-
crease in PSA velocity. Finally changes in DRE findings as
well as evidence of radiological progression of the tumour
would prompt radical treatment in more than 50 % of
cases (Fig. 4).
Comparison with other network trusts
The same questionnaire was sent out to members of trusts
part of two other UK cancer networks. We received a total
of 10 responses, five from each cancer network. The find-
ings were very comparable to our own network. There
was broad agreement that men under 50 years would not
be suitable for AS. In both networks surveyed, there was
significant variation in respondent’s views on inclusion cri-
teria for AS (Fig. 5a). Similar to our data, most respon-
dents would include Gleason grade 7 patients in an active
surveillance programme but dependent on other clinical
characteristics. In one of the two networks studied, a
significant number of respondents advocated MRI and
transperineal repeat biopsies as part of their assessment
of patients suitability for AS. However only a minorityFig. 4 Respondents views on criteria that would trigger conversion to activof respondents in the other network used any additional
biopsy or imaging in evaluating patients suitability. On
the question of timing of repeat biopsies there was again
variability in the responses (Fig. 5b). The majority advo-
cated re-biopsy at 12 or 18 months after entry onto an AS
programme. Finally, we compared triggers to initiate a
change in management. Here there was broad consistency
in terms of what would initiate a change and included an
increase in grade and/or tumour volume. This comparison
demonstrated that the lack of dedicated resources and
variability in inclusion and follow up in AS is likely to be a
universal issue across the NHS.
Discussion
In contemporary UK practice LRPC accounts for 20 %
of all new prostate cancer diagnoses [6]. The perception
that LRPC is over-treated has gained the ascendancy
among the urological community following results from
randomised studies such as the European Randomised
Study of Screening for Prostate Cancer (ERSPC) trial [7]
and Prostate Cancer Intervention vs Observation Trial
(PIVOT) [8]. It is therefore easy to foresee that AS will
most likely become the preferred option of managing pa-
tients with LRPC. The UK NICE guidelines define men
suitable for AS as having the following characteristics: clin-
ical stage T1c; a Gleason score of 3 + 3; a PSA density of <
0.15 ng/mL/mL; and cancer in < 50 % of their total number
of biopsy cores with < 10 mm of any core involved (http://
guidance.nice.org.uk/CG175) [5]. These recommendations
are very similar to the European, American and Canadian
urological guidelines which universally recommend that
AS is suitable for patients with Gleason score of 6 or
less [1, 2, 9]. Our survey demonstrated that the NICE
guidelines regarding AS enrolment are generally followed.
However, in certain cases patients are being recruited into
AS programmes with characteristics of intermediate-riske treatment
Fig. 5 a Respondents views on enrolment criteria for AS from the two geographically distinct cancer networks surveyed. b Respondents views
on how they follow up patients on AS from the two geographically distinct cancer networks surveyed
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Table 3 Selection criteria for Active Surveillance in international published series
Publication Gleason Score PSA (ng/ml) Positive cores % positive biopsy cores % cancer involvement
per core
cT
Dall’ Era [11] ≤6 <10 - <33 - ≤2a
Bul [10] ≤7 <20 ≤3 - - -
Soloway [12] ≤6 ≤10 ≤2 - <20 ≤2
Tosoian [18] ≤6 ≤10 ≤2 - <50 1c
Ercole [13] ≤6 <10 ≤2 - <50 ≤2a
Klotz [14] ≤6 ≤10 - - - ≤2b
Ischia [15] ≤6 <10 - - - ≤2a
Thomsen [16] ≤6 ≤10 ≤3 - <50 ≤2a
Selvadurai [17] ≤6 <15 - ≤50 - ≤2
cT clinical tumour category, PSA prostate specific antigen
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dents considered men for AS who had T2b or T2c disease,
a PSA of 10–20 ng/ml, a Gleason score of 7 and patients
with tumour involvement of more than 50 % of their total
biopsy cores. This reflects that routine UK practice of AS
commonly outstretches that described in most inter-
national published series of AS and also the recommenda-
tions of European, American and Canadian urological
guidelines. Encouragingly however, there was a general
agreement between our respondents as to the criteria that
would trigger conversion to radical treatment.
Our survey demonstrated the marked heterogeneity
which exists in the practice of AS across our cancer net-
work. This variability is not unique to our cancer net-
work alone but also evident in other cancer networks
too in geographically distinct areas of the UK. This strik-
ing variability in AS enrolment criteria, follow up and
triggers for intervention is also demonstrated in inter-
national and national series of AS (Tables 3 and 4). In
these studies, patients were followed up with a combin-
ation of repeat biopsies, serial PSA measurements and
clinical examination. The frequency of repeat biopsies
varied widely analogous to our own cancer network.
Some carried out biopsies annually [10–12], while others
every 2 or 3 years [13–16], and in some depending on
clinical characteristics [17, 18]. Almost unanimously inTable 4 Triggers to treatment used in patients under Active Surveill
Publication Gleason Score on
repeat biopsy
Positive cores % cancer involve
per single core
Dall’Era [11] Progression - -
Tosoian [18] >6 >2 >50
Ercole [13] Progression Increase Increase
Klotz [14] ≥4 - -
Ischia [15] Progression - -
Thomsen [16] ≥3 + 4 >3 -
Selvadurai [17] ≥4 + 3 - -
cT clinical tumour category, PSAdt prostate-specific antigen doubling time, PSAv PSAthe studies we reviewed tumour upgrading on repeat bi-
opsy would prompt a recommendation for treatment.
Some studies also considered an increase in tumour vol-
ume or percentage of core biopsies involved as a trigger
to radical treatment. PSA doubling time or velocity was
also sometimes a trigger to proceed to radical treatment.
The updated NICE guidance has advocated the use of
mpMRI at the time of AS enrolment followed by a re-
peat biopsy at year one and has put in place a follow up
regime as its key suggestions. To understand what the
impact of these recommendations would be on routine
clinical practice, our survey assessed the current reported
patterns of practice. Amongst our respondents only 40 %
of respondents performed a repeat biopsy at 12 months
and only 60 % use mpMRI routinely as a tool for selecting
patients suitable for AS. It should be noted however that
although the NICE guidelines have clearly stated that
mpMRI should occur at the time of AS enrolment, the
EUA and AUA guidelines are not so prescriptive. Similarly
Canadian urological guidelines from Ontario recommend
that mpMRI may be included in AS protocols but is not
currently a necessity [1, 2, 9]. In contrast, the recommen-
dation on 3–4 monthly PSA checks is consistent with
current routine practice in our survey. Even so there will
need to be a method to monitor and track the PSA. Simi-
larly recommendations for DRE every 6–12 months isance
ment % positive
biopsy cores
PSAdt cT (years) PSAv
(ng/ml/year)
cT
- - >0.75 -
- - - -
- - - Upstage
- 3 - -
- - - Upstage
- 3 - Upstage
>50 - >1 -
velocity
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our survey there was great variability in who did the AS
follow up including DRE. Moreover 40 % of respondents
did not routinely perform a DRE during the follow up ap-
pointment. Again adherence to the NICE guidelines will
require a significant change in practice and ideally necessi-
tate consistency in AS follow up providers.
From the results of this survey it is quite clear that the
implementation of a robust and consistent AS program
according to the recommendations of the NICE guide-
lines will prove challenging due to the current variation
in its practice. In addition the burden of follow-up with
clinical examinations and serum PSA testing on both men
and healthcare systems is far from cost-neutral. Even more
so the use of novel strategies such as mpMRI at the time
of AS enrollment will further put a strain on radiology
providers. It is clear that in addition to reducing the vari-
ability in the practice of AS there is also the need for ro-
bust cost-effectiveness studies to ensure that such novel
strategies are both clinically and cost-effective.
This study however does not come without its limita-
tions. Firstly the methodology of this study is a question-
naire survey study with a total of 35 respondents which
is a low number of participants and may not accurately
depict the practice of AS within the EoE cancer network.
Also this study was UK specific and may not mirror the
trends in the world-wide practice of AS though our review
of other international published series of AS did demon-
strate variability in its practice. Furthermore the majority
of our respondents were from primarily academic institu-
tions therefore it is likely that the practice of AS is even
more heterogeneous outside the academic setting.
Conclusions
Despite its limitations, the present survey has demon-
strated the marked heterogeneity in which AS is prac-
ticed across a cancer network in the UK. This is also
mirrored across other hospitals in the UK. It is clear that
if the NICE guidelines are adopted then the resource re-
quirements are likely to be very significant and not cur-
rently in place across the UK. These issues need urgent
resolution and now is the time for a national discussion
and planning. This would provide the much needed re-
assurance to clinicians and patients of the robustness of
an AS programme on a par with current standard thera-
peutic options.
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